Cure8 trial brief
The trial is testing risankizumab alone and in combination with investigational ABBV antibodies for moderate-to-severe Crohn’s disease and ulcerative colitis — findings could inform future treatment choices and combination strategies.
Adults with moderately to severely active Crohn's disease or ulcerative colitis; patients on biologics; IBD clinicians and researchers interested in new biologic combinations.
This is a multiarm, two-substudy Phase 2 interventional trial run by AbbVie that will enroll adults with moderately to severely active Crohn's disease or ulcerative colitis.
Substudy 1 and Substudy 2 each compare risankizumab alone and in combination with investigational antibodies (trosunilimab / ABBV-701) across blinded treatment arms after an initial unblinded substudy assignment.
The study plans frequent clinic visits with medical assessments, blood and stool tests, endoscopies, and patient questionnaires; participants may face greater time and testing burden than standard care.
Primary outcomes include endoscopic remission measured at Week 28 for Crohn's and UC-specific eligibility/stratification criteria are described in the record.
This is a Phase 2 interventional study record (not yet recruiting) and contains study design and planned outcomes but no clinical results. Investigational agents and combination strategies are under study; participation may involve higher visit and testing burden than standard care.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
An FDA approval means another biologic option is available for Crohn’s disease, which could affect treatment choices and insurance coverage. The approval also signals pharma competition and pipeline activity that may...
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.
